Lead Product(s) : Xanamem
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Actinogen’s Xanamem® Shows Superiority in Depression in Phase 2a XanaCIDD Trial
Details : Xanamem (UE2343) blocks the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. It is being developed for the treatment of major depressive disorder.
Product Name : Xanamem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2024
Lead Product(s) : Xanamem
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MindBio Reports Phase 2A Trial: Improved Outcomes in Depressed Patients
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Product Name : MB22001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xanamem
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Actinogen announces Further Positive Results on Depression in the XanCIDD Phase 2a Trial
Details : Xanamem (UE2343) blocks the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. It is being developed for the treatment of major depressive disorder.
Product Name : Xanamem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Xanamem
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MindBio Reports Sustained Antidepressant Response 3-Months Post Microdosing
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Product Name : MB22001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MindBio Reports Sustained Antidepressant Response from MB22001 in Depression Trials
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Product Name : MB22001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xanamem
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enrolment Completed in Actinogen's XanaCIDD Phase 2a Cognition & Depression Trial
Details : Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. It is being developed for major depressive disorder.
Product Name : Xanamem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2024
Lead Product(s) : Xanamem
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MindBio Receives Approval for Phase 2B Microdosing Mb22001 in Major Depressive Disorder
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Product Name : MB22001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Incannex Reports Positive Results from Phase 2 Psi-GAD1 Trial Of Psilocybin
Details : PSX-001 (psilocybin) is a serotonin (5-HT2A) receptor agonist, currently in phase 2 trials for the treatment of patients with generalised anxiety disorder.
Product Name : PSX-001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MindBio Therapeutics Reports Positive Depression Data from Phase 2a Microdosing Trial
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Product Name : MB22001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
Details : MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Product Name : MB22001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable